NSG 5240 Advanced Pharmacology Final Practice
Exam – Real Questions South College NP
Program | Latest | Bold Answers with Detailed
Solutions Latest Update This Year | Instant Pdf
Download
Introduction
This comprehensive practice exam is designed for students preparing for the NSG 5240 Advanced
Pharmacology Final Exam at South College . The exam covers advanced pharmacotherapeutic principles
across multiple body systems and disease states at the graduate level .
Core Content Domains :
Pharmacokinetics & Pharmacodynamics – ADME, first-pass effect, half-life, steady state,
volume of distribution, cytochrome P450 enzymes, drug interactions, therapeutic index
Autonomic & Cardiovascular Pharmacology – HFrEF management, hypertension,
anticoagulation, antiplatelet therapy, digoxin, amiodarone, statins
Endocrine & Metabolic Agents – Diabetes mellitus, thyroid disorders, adrenal disorders,
osteoporosis, gout
CNS & Psychiatric Medications – Antidepressants, antipsychotics, anxiolytics, mood stabilizers,
anticonvulsants, Alzheimer's, Parkinson's
Anti-infective Agents – Antibiotics, antifungals, antivirals
Pain Management – Opioids, NSAIDs, neuropathic pain agents
Special Populations – Pregnancy, pediatrics, geriatrics, pharmacogenomics
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1-25)
,1. A drug has a half-life of 12 hours. How many hours will it take to reach steady
state?
A. 24 hours
B. 36 hours
C. 48 hours
D. 60 hours
: Steady state is achieved after approximately 4-5 half-lives of continuous dosing. 5 × 12
hours = 60 hours. At 4 half-lives, 94% of steady state is reached; at 5 half-lives, 97% .
2. A patient with liver cirrhosis has reduced metabolism of a drug that normally
undergoes extensive first-pass effect. How will this affect the oral dose of the drug?
A. Increased first-pass metabolism
B. Decreased bioavailability
C. Significantly increased bioavailability
D. No change in drug levels
: The first-pass effect occurs in the liver. Liver impairment means less drug is metabolized
before reaching systemic circulation, leading to higher bioavailability and potential toxicity .
3. Which route of administration bypasses the first-pass effect?
A. Oral
B. Sublingual
C. Rectal
D. Both B and C
: Sublingual and rectal administration allow absorption directly into systemic circulation,
partially or fully avoiding portal circulation and first-pass metabolism in the liver .
4. A drug's steady-state concentration is determined primarily by:
,A. Dose and dosing interval
B. Clearance and bioavailability
C. Volume of distribution only
D. Half-life only
: Steady-state concentration (Css) = (Dose × F) / (Clearance × τ). Clearance is the most
important determinant of steady-state concentration .
5. A patient with chronic kidney disease requires a medication adjustment. Which
pharmacokinetic process is most significantly altered?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
: The kidneys handle elimination for most drugs. Reduced glomerular filtration rate impairs
clearance and raises toxicity risk, requiring dose adjustments based on creatinine
clearance .
6. A drug with a high volume of distribution (Vd) primarily indicates:
A. The drug is highly protein-bound
B. The drug is confined to the vascular space
C. The drug extensively distributes into tissues
D. The drug has a short half-life
: A high Vd (>0.6 L/kg) suggests the drug has left the plasma and entered tissues, often due
to lipophilicity or tissue binding. High protein binding usually decreases Vd by keeping drug
in vascular space .
, 7. Which cytochrome P450 enzyme is most commonly involved in drug-drug
interactions?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9
: CYP3A4 metabolizes >50% of all drugs and is inhibited/induced by many agents (e.g.,
grapefruit juice, rifampin, ketoconazole) .
8. A patient develops tolerance to morphine after chronic use. This is most likely due
to:
A. Decreased absorption
B. Increased renal excretion
C. Receptor downregulation
D. Increased plasma protein binding
: Chronic agonist exposure often leads to receptor downregulation or desensitization,
requiring higher doses for the same effect .
9. A patient is on rifampin (a CYP3A4 inducer) and an oral contraceptive. The NP
should:
A. Increase contraceptive dose
B. Switch to depot medroxyprogesterone
C. Recommend backup contraception
D. No interaction is expected
: Inducers like rifampin reduce contraceptive hormone levels, increasing the risk of
unintended pregnancy. A backup or alternative method is needed .
Exam – Real Questions South College NP
Program | Latest | Bold Answers with Detailed
Solutions Latest Update This Year | Instant Pdf
Download
Introduction
This comprehensive practice exam is designed for students preparing for the NSG 5240 Advanced
Pharmacology Final Exam at South College . The exam covers advanced pharmacotherapeutic principles
across multiple body systems and disease states at the graduate level .
Core Content Domains :
Pharmacokinetics & Pharmacodynamics – ADME, first-pass effect, half-life, steady state,
volume of distribution, cytochrome P450 enzymes, drug interactions, therapeutic index
Autonomic & Cardiovascular Pharmacology – HFrEF management, hypertension,
anticoagulation, antiplatelet therapy, digoxin, amiodarone, statins
Endocrine & Metabolic Agents – Diabetes mellitus, thyroid disorders, adrenal disorders,
osteoporosis, gout
CNS & Psychiatric Medications – Antidepressants, antipsychotics, anxiolytics, mood stabilizers,
anticonvulsants, Alzheimer's, Parkinson's
Anti-infective Agents – Antibiotics, antifungals, antivirals
Pain Management – Opioids, NSAIDs, neuropathic pain agents
Special Populations – Pregnancy, pediatrics, geriatrics, pharmacogenomics
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1-25)
,1. A drug has a half-life of 12 hours. How many hours will it take to reach steady
state?
A. 24 hours
B. 36 hours
C. 48 hours
D. 60 hours
: Steady state is achieved after approximately 4-5 half-lives of continuous dosing. 5 × 12
hours = 60 hours. At 4 half-lives, 94% of steady state is reached; at 5 half-lives, 97% .
2. A patient with liver cirrhosis has reduced metabolism of a drug that normally
undergoes extensive first-pass effect. How will this affect the oral dose of the drug?
A. Increased first-pass metabolism
B. Decreased bioavailability
C. Significantly increased bioavailability
D. No change in drug levels
: The first-pass effect occurs in the liver. Liver impairment means less drug is metabolized
before reaching systemic circulation, leading to higher bioavailability and potential toxicity .
3. Which route of administration bypasses the first-pass effect?
A. Oral
B. Sublingual
C. Rectal
D. Both B and C
: Sublingual and rectal administration allow absorption directly into systemic circulation,
partially or fully avoiding portal circulation and first-pass metabolism in the liver .
4. A drug's steady-state concentration is determined primarily by:
,A. Dose and dosing interval
B. Clearance and bioavailability
C. Volume of distribution only
D. Half-life only
: Steady-state concentration (Css) = (Dose × F) / (Clearance × τ). Clearance is the most
important determinant of steady-state concentration .
5. A patient with chronic kidney disease requires a medication adjustment. Which
pharmacokinetic process is most significantly altered?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
: The kidneys handle elimination for most drugs. Reduced glomerular filtration rate impairs
clearance and raises toxicity risk, requiring dose adjustments based on creatinine
clearance .
6. A drug with a high volume of distribution (Vd) primarily indicates:
A. The drug is highly protein-bound
B. The drug is confined to the vascular space
C. The drug extensively distributes into tissues
D. The drug has a short half-life
: A high Vd (>0.6 L/kg) suggests the drug has left the plasma and entered tissues, often due
to lipophilicity or tissue binding. High protein binding usually decreases Vd by keeping drug
in vascular space .
, 7. Which cytochrome P450 enzyme is most commonly involved in drug-drug
interactions?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9
: CYP3A4 metabolizes >50% of all drugs and is inhibited/induced by many agents (e.g.,
grapefruit juice, rifampin, ketoconazole) .
8. A patient develops tolerance to morphine after chronic use. This is most likely due
to:
A. Decreased absorption
B. Increased renal excretion
C. Receptor downregulation
D. Increased plasma protein binding
: Chronic agonist exposure often leads to receptor downregulation or desensitization,
requiring higher doses for the same effect .
9. A patient is on rifampin (a CYP3A4 inducer) and an oral contraceptive. The NP
should:
A. Increase contraceptive dose
B. Switch to depot medroxyprogesterone
C. Recommend backup contraception
D. No interaction is expected
: Inducers like rifampin reduce contraceptive hormone levels, increasing the risk of
unintended pregnancy. A backup or alternative method is needed .
